{"entity":{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","aka":[],"tldr":"The trial that added toripalimab to chemotherapy for oesophageal cancer in China and showed a survival gain regardless of PD-L1 level.","summary":"514 patients. Median overall survival 17.0 versus 11.0 months (hazard ratio 0.58) and progression-free survival 5.7 versus 5.5 months (hazard ratio 0.58) at the interim analysis, with benefit independent of PD-L1 expression; published in Cancer Cell 2022. NMPA approval May 2022. One of five Chinese PD-1 trials (with ESCORT-1st, ORIENT-15, RATIONALE-306 and KEYNOTE-590) that made chemo-immunotherapy the first-line standard in a cancer where China has about half the world's cases.","status":"positive","asOf":"2026-09-10","links":[{"label":"ClinicalTrials.gov NCT03829969","url":"https://clinicaltrials.gov/study/NCT03829969"},{"label":"Cancer Cell 2022","url":"https://doi.org/10.1016/j.ccell.2022.02.007"}],"tags":["china"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab","paclitaxel","cisplatin"],"companies":["junshi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["xu-rui-hua"],"bottlenecks":[],"keyPapers":["paper-wang-cancer-cell"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03829969","phase":"3","setting":"First-line advanced oesophageal squamous cell carcinoma, China: toripalimab or placebo plus paclitaxel and cisplatin","sponsor":"Shanghai Junshi Biosciences","result":"OS 17.0 vs 11.0 months (HR 0.58); PFS HR 0.58.","started":"2019-01-31","startedType":"actual","yearReported":2022,"enrolled":514,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Toripalimab + TP","n":257,"value":17},{"name":"Placebo + TP","n":257,"value":11}],"hr":0.58,"source":"https://doi.org/10.1016/j.ccell.2022.02.007"}]},"route":"/trials/jupiter-06/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/"}],"person":[{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/"}],"paper":[{"id":"paper-wang-cancer-cell","kind":"paper","name":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","route":"/key-papers/paper-wang-cancer-cell/"}]}}